Barinthus Biotherapeutics (BRNS) Intangibles (2021 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Intangibles came in at $13.7 million in Q1 2026, down 35.4% YoY from $21.2 million in Q1 2025, and down 4.35% on a QoQ basis from $14.3 million in Q4 2025.
Barinthus Biotherapeutics (BRNS) Intangibles (2021 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 6 years of Intangibles data on file, last reported at $13.7 million in Q1 2026.
- Quarterly Intangibles fell 35.4% year-over-year to $13.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.7 million (down 35.4% YoY) and the FY2025 annual result came in at $14.3 million, down 34.9% from the prior year.
- Intangibles fell to $13.7 million in Q1 2026, from $14.3 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $30.6 million in Q1 2022 to a low of $13.7 million in Q1 2026.
- A 5-year average of $23.5 million and a median of $24.3 million in 2024 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2022 — Intangibles dropped 10.06% — and 2026, when it plunged 35.4%.
- Tracing BRNS's Intangibles over 5 years: stood at $28.3 million in 2022, then retreated by 11.18% to $25.1 million in 2023, then retreated by 12.59% to $21.9 million in 2024, then sank by 34.9% to $14.3 million in 2025, then retreated by 4.35% to $13.7 million in 2026.
- The last three Intangibles figures came in at $13.7 million (Q1 2026), $14.3 million (Q4 2025), and $14.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Barinthus Biotherapeutics | 25.40 Mn | 25.40 Mn | - | 13.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.05 Mn |
| Mar 31, 2026 | 13.67 Mn |
| Dec 31, 2025 | 14.29 Mn |
| Sep 30, 2025 | 14.91 Mn |
| Jun 30, 2025 | 20.37 Mn |
| Mar 31, 2025 | 21.16 Mn |
| Dec 31, 2024 | 21.95 Mn |
| Sep 30, 2024 | 22.74 Mn |
| Jun 30, 2024 | 23.53 Mn |
| Mar 31, 2024 | 24.32 Mn |
| Dec 31, 2023 | 25.11 Mn |
| Sep 30, 2023 | 25.90 Mn |
| Jun 30, 2023 | 26.69 Mn |
| Mar 31, 2023 | 27.48 Mn |
| Dec 31, 2022 | 28.27 Mn |
| Sep 30, 2022 | 29.06 Mn |
| Jun 30, 2022 | 29.85 Mn |
| Mar 31, 2022 | 30.64 Mn |
| Dec 31, 2021 | 31.43 Mn |